ZIPALERTINIB

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

April, 2025

ZIPALERTINIB

Feb 4, 2025, 10:31 | Insight

Stephen V Liu: The Phase 2b REZILIENT1 study of zipalertinib met its primary endpoint

Stephen V Liu, Associate Professor of Medicine at Georgetown University, Director of Thoracic Oncology and Head…

Dec 29, 2024, 10:00 | Drugs

Giannis Mountzios: 10 exciting compounds that will shape lung cancer in 2025

Giannis Mountzios, Consultant Medical Oncologist at the Department of Medical Oncology in the Air force…

All: 2 Posts: 1 - 100

'

Where to Study to Become ASCO President: 2025 Institutional Rankings

'

Yelak Biru: UK grants first approval for Blenrep in multiple myeloma

'

Eric Abidal and Liver Cancer: How He Returned to Football After Overcoming Illness

'

Dr. Don Dizon and Dr. Nathan Pennell Reflect on the Evolution of the ASCO Educational Book

'

April is Head and Neck Cancer Awareness Month

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023